CN101784675B - 用于剥脱性综合征和青光眼的诊断、预后和治疗的标记物的chr 15q24上的遗传变异 - Google Patents

用于剥脱性综合征和青光眼的诊断、预后和治疗的标记物的chr 15q24上的遗传变异 Download PDF

Info

Publication number
CN101784675B
CN101784675B CN200880103034.6A CN200880103034A CN101784675B CN 101784675 B CN101784675 B CN 101784675B CN 200880103034 A CN200880103034 A CN 200880103034A CN 101784675 B CN101784675 B CN 101784675B
Authority
CN
China
Prior art keywords
glaucoma
markers
risk
seq
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880103034.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN101784675A (zh
Inventor
古德马尔·索尔莱夫松
克里斯廷·P·马格努松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics ehf filed Critical Decode Genetics ehf
Publication of CN101784675A publication Critical patent/CN101784675A/zh
Application granted granted Critical
Publication of CN101784675B publication Critical patent/CN101784675B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880103034.6A 2007-06-13 2008-06-13 用于剥脱性综合征和青光眼的诊断、预后和治疗的标记物的chr 15q24上的遗传变异 Expired - Fee Related CN101784675B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IS8651 2007-06-13
IS8651 2007-06-13
IS8664 2007-07-13
IS8664 2007-07-13
IS8668 2007-08-08
IS8668 2007-08-08
PCT/IS2008/000014 WO2008152656A2 (en) 2007-06-13 2008-06-13 Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma

Publications (2)

Publication Number Publication Date
CN101784675A CN101784675A (zh) 2010-07-21
CN101784675B true CN101784675B (zh) 2014-10-29

Family

ID=39869955

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880103034.6A Expired - Fee Related CN101784675B (zh) 2007-06-13 2008-06-13 用于剥脱性综合征和青光眼的诊断、预后和治疗的标记物的chr 15q24上的遗传变异

Country Status (12)

Country Link
US (1) US20090035279A1 (enExample)
EP (1) EP2179062A2 (enExample)
JP (1) JP2010533477A (enExample)
KR (1) KR20100037592A (enExample)
CN (1) CN101784675B (enExample)
AU (1) AU2008263384B2 (enExample)
CA (1) CA2690671A1 (enExample)
IL (1) IL202674A0 (enExample)
MX (1) MX2009013649A (enExample)
NZ (1) NZ582131A (enExample)
SG (1) SG182159A1 (enExample)
WO (1) WO2008152656A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004404A1 (en) * 2009-07-10 2011-01-13 Decode Genetics Ehf Genetic variants for predicting risk of glaucoma
US9107617B2 (en) 2009-11-16 2015-08-18 Agency For Science, Technology And Research Obtaining data for automatic glaucoma screening, and screening and diagnostic techniques and systems using the data
US20110195457A1 (en) * 2010-02-09 2011-08-11 General Electric Company Isothermal amplification of nucleic acid using primers comprising a randomized sequence and specific primers and uses thereof
GB201021457D0 (en) * 2010-12-17 2011-02-02 Univ Manchester Anti-ageing agents
JP2014516514A (ja) * 2011-04-14 2014-07-17 コンプリート・ジェノミックス・インコーポレイテッド 複合核酸配列データの処理および解析
US8718950B2 (en) 2011-07-08 2014-05-06 The Medical College Of Wisconsin, Inc. Methods and apparatus for identification of disease associated mutations
RU2495420C1 (ru) * 2012-10-11 2013-10-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезний имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации Способ дифференциальной диагностики раноприобретенной и врожденной прогрессирующей миопии
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
CN109074426B (zh) 2016-02-12 2022-07-26 瑞泽恩制药公司 用于检测异常核型的方法和系统
JP7072803B2 (ja) * 2016-06-30 2022-05-23 京都府公立大学法人 広義原発開放隅角緑内障の発症リスクの判定方法
CN106529558B (zh) * 2016-10-28 2019-05-24 北京化工大学 青光眼图像特征提取方法及装置
CN106978509B (zh) * 2017-06-07 2018-10-26 中南大学湘雅二医院 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用
CN110272996A (zh) * 2019-07-31 2019-09-24 汶上县中医院 与青光眼发生发展相关的生物标志物及其应用
WO2021173712A1 (en) * 2020-02-24 2021-09-02 The Board Of Regents Of The University Of Texas System Molecular biomarkers and targets for fuchs' endothelial corneal dystrophy and glaucoma
CN112684186B (zh) * 2020-12-31 2022-04-01 华中科技大学 用于预测2型糖尿病患者发生mci风险的生物标志物和试剂盒及其应用
CN113430263B (zh) * 2021-08-27 2021-11-05 中国医学科学院北京协和医院 基于生物标志物的诊断青光眼的产品及其应用
CN115691662B (zh) * 2022-11-08 2023-06-23 温州谱希医学检验实验室有限公司 基于变构概率对近视/高度近视相关snp风险的排序方法和系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197621A (en) * 1960-12-30 1965-07-27 Ibm Real time control system for processing main and incremental quantities
US3705942A (en) * 1969-09-29 1972-12-12 Ciba Geigy Corp Treatment of glaucoma employing imipramine or desmethylimipramine
CA2217097A1 (en) * 1997-09-30 1999-03-30 Jean-Louis Anctil Molecular diagnostic of glaucomas associated with chromosomes 2 and 6
JP2002306165A (ja) * 2000-05-17 2002-10-22 Tsubota:Kk 正常眼圧緑内障を含む開放隅角緑内障の関連遺伝子
US20040091914A1 (en) * 2002-08-02 2004-05-13 Sysmex Corporation Gene assay method for predicting glaucoma onset risk
US7255856B2 (en) * 2004-01-23 2007-08-14 Massachusetts Eye & Ear Infirmary Lysyl oxidase-like 1 (LOXL1) and elastogenesis
WO2006068829A1 (en) * 2004-12-21 2006-06-29 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
尚颖萍 等.小梁切除联合前房注入肾上腺素治疗新生血管性青光眼.《浙江实用医学》.2003,第8卷(第5期),307页. *
王于蓝 等.拉坦前列腺素的临床疗效及副作用观察.《上海第二医科大学学报》.2003,第23卷第104-106页. *

Also Published As

Publication number Publication date
AU2008263384B2 (en) 2014-08-28
WO2008152656A2 (en) 2008-12-18
WO2008152656A3 (en) 2009-02-05
MX2009013649A (es) 2010-01-27
CN101784675A (zh) 2010-07-21
KR20100037592A (ko) 2010-04-09
EP2179062A2 (en) 2010-04-28
SG182159A1 (en) 2012-07-30
NZ582131A (en) 2012-07-27
US20090035279A1 (en) 2009-02-05
JP2010533477A (ja) 2010-10-28
AU2008263384A1 (en) 2008-12-18
IL202674A0 (en) 2011-08-01
CA2690671A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
CN101784675B (zh) 用于剥脱性综合征和青光眼的诊断、预后和治疗的标记物的chr 15q24上的遗传变异
CN101874120B (zh) 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型
KR102694809B1 (ko) Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
CN101238222B (zh) 作为2型糖尿病风险诊断标记物的tcf7l2基因的遗传变异体
DK2471954T3 (en) Susceptibility genetic variants associated with cardiovascular diseases
CA2566256C (en) Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
AU2015360694B2 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN107941681B (zh) 鉴定生物样品中定量细胞组成的方法
DK2414543T3 (en) Genetic markers for risk management of atrial fibrillation and stroke
US20040018525A1 (en) Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
KR20110081807A (ko) 갑상선암의 위험도 평가를 위해 유용한 유전적 변이
KR20110036608A (ko) 유방암 위험도 평가를 위한 유전적 변이
CN101641451A (zh) chr8q24.21上的癌症易感性变体
US20090305284A1 (en) Methods for Identifying Risk of Breast Cancer and Treatments Thereof
KR20100017865A (ko) 유방암의 위험도 평가, 진단, 예후 및 치료용 마커인 염색체 ５ｐ１２ 및 염색체 １０ｑ２６ 상의 유전적 변이
KR20110015409A (ko) 염증성 장 질환에 대한 유전자 발현 마커
KR20150023904A (ko) 전립선암의 진단 및 치료에서의 마커의 용도
CN102317470A (zh) 促进前列腺癌风险的遗传性变型
CN107532200A (zh) 用于对pkd1基因及pkd2基因的外显子进行扩增的引物组及方法
US20030099958A1 (en) Diagnosis and treatment of vascular disease
KR101818352B1 (ko) 방광암의 진단 및 예후 예측용 바이오 마커 및 그의 용도
CA2651376A1 (en) Method for diagnosis and treatment of a mental disease
TW202309298A (zh) 大動脈動脈粥樣硬化症的缺血性腦中風的發病時期預測方法
WO1999055915A2 (en) IDENTIFICATION OF POLYMORPHISMS IN THE PCTG4 REGION OF Xq13
IL179831A (en) In vitro method for detecting the presence of or predisposition to autism or to an autism spectrum disorder, and an in vitro method of selecting biologically active compounds on autism or autism spectrum disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141029

Termination date: 20150613

EXPY Termination of patent right or utility model